1. Home
  2. CTY vs OBX Comparison

CTY vs OBX Comparison

Compare CTY & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTY

City Therapeutics Inc. Common Stock

N/A

Current Price

$17.55

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Obsidian Therapeutics Inc. Common Stock

OBX

Obsidian Therapeutics Inc. Common Stock

N/A

Current Price

$13.10

Market Cap

848.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTY
OBX
Founded
2023
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
848.8M
IPO Year
2026
2026

Fundamental Metrics

Financial Performance
Metric
CTY
OBX
Price
$17.55
$13.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$37.33
★ $38.67
AVG Volume (30 Days)
250.4K
★ 531.9K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$62.96
N/A
Revenue Next Year
$7.47
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.81
$9.60
52 Week High
$22.65
$39.00

Technical Indicators

Market Signals
Indicator
CTY
OBX
Relative Strength Index (RSI) 41.04 48.71
Support Level $16.12 $11.84
Resistance Level $21.98 $15.87
Average True Range (ATR) 2.35 1.74
MACD -0.15 0.04
Stochastic Oscillator 25.44 59.12

Price Performance

Historical Comparison
CTY
OBX

About CTY City Therapeutics Inc. Common Stock

City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.

About OBX Obsidian Therapeutics Inc. Common Stock

Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.

Share on Social Networks: